Veracyte VCYT Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 70.9%+2.9pp | 70.1%+3.2pp | 68.5%+1.7pp | 68.3%+2.5pp | 68%+3.9pp | |
| Operating margin | 14.3%+9.2pp | 11.2%+7.6pp | 5%+10.5pp | 2.9%+19.7pp | 5.1%+26.4pp | |
| Net margin | 16.2%+9.1pp | 12.8%+7.4pp | 6.1%+8.3pp | 5.5%+19.0pp | 7.1%+25.3pp | |
| EBITDA margin | 18.3%+8.1pp | 15.3%+6.4pp | 9.5%+9.5pp | 7.7%+18.3pp | 10.1%+24.5pp | |
| Free cash flow margin | 28.7%+11.7pp | 24.5%+10.2pp | 19.8%+6.6pp | 17.5%— | 16.9%— | |
| Returns | ||||||
| Return on equity | 6.9%+4.1pp | 5.3%+3.2pp | 2.5%+3.3pp | 2.2%+7.1pp | 2.9%+9.1pp | |
| Return on assets | 6.4%+3.8pp | 4.9%+2.9pp | 2.3%+3.1pp | 2%+6.6pp | 2.6%+8.4pp | |
| Return on invested capital | 7.1%+4.7pp | 5.9%+4.1pp | 2.6%+5.2pp | 1.4%+8.8pp | 2.4%+11.1pp | |
| Efficiency | ||||||
| Asset turnover | 0.4×0.0× | 0.4×0.0× | 0.4×0.0× | 0.4×0.0× | 0.4×0.0× | |
| Liquidity | ||||||
| Current ratio | 9.3×+4.2× | 8.1×+3.4× | 6.2×+1.2× | 5.4×+1.0× | 5.1×+0.1× | |
| Quick ratio | 9.3×+4.5× | 7.8×+3.3× | 5.9×+1.2× | 5.1×+0.9× | 4.8×+0.1× | |
| Cash ratio | 4.7×+2.2× | 6.1×+3.0× | 4.4×+0.5× | 2.9×-0.4× | 2.5×-1.1× | |
| Leverage | ||||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Debt-to-assets | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Net debt / EBITDA | -2.3×— | -4.1×— | -5.9×— | -4.6×— | —— | |
| Per Share | ||||||
| Book value per share | $16.53+10.8% | $16.25+8.0% | $15.78+5.3% | $15.58+6.1% | $14.93-0.2% | |
| Valuation | ||||||
| Market capitalization | $2.56B+10.7% | $3.33B+8.4% | $2.7B+3.7% | $2.11B+29.9% | $2.31B+43.6% | |
| Enterprise value | $2.33B+7.4% | $3B+4.3% | $2.42B+3.2% | $1.93B+37.8% | $2.17B+53.8% | |
| Price / earnings | 29.1×— | 50.2×— | 89.1×— | —— | —— | |
| Price / sales | 4.7×-0.3× | 6.4×-0.4× | 5.5×-0.7× | 4.4×+0.3× | 5×+0.7× | |
| Price / book | 1.9×0.0× | 2.5×-0.1× | 2.1×-0.1× | 1.7×+0.3× | 1.9×+0.5× | |
| EV / EBITDA | 23.6×— | 37.9×— | 51.4×— | 52.6×— | —— | |
| EV / sales | 4.3×-0.4× | 5.8×-0.7× | 4.9×-0.6× | 4×+0.5× | 4.7×+0.9× | |
| Free cash flow yield | 6.1%+2.7pp | 3.8%+1.7pp | 3.6%+1.5pp | 4%— | 3.4%— | |
| Earnings yield | 3.4%+2.0pp | 2%+1.2pp | 1.1%+1.5pp | 1.3%+4.6pp | 1.4%+5.7pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Veracyte's profit margins?
- Veracyte (VCYT) runs a 70.9% gross margin and a 14.3% operating margin, with a 16.2% net margin.
- Where do Veracyte's ratios come from?
- Every ratio is computed from Veracyte's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.